LITHONATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lithonate, and when can generic versions of Lithonate launch?
Lithonate is a drug marketed by Solvay and is included in two NDAs.
The generic ingredient in LITHONATE is lithium citrate. There are fifteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lithium citrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lithonate
A generic version of LITHONATE was approved as lithium citrate by RUBICON on August 14th, 2023.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LITHONATE?
- What are the global sales for LITHONATE?
- What is Average Wholesale Price for LITHONATE?
Summary for LITHONATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 133 |
| Clinical Trials: | 3 |
| Patent Applications: | 2,019 |
| DailyMed Link: | LITHONATE at DailyMed |
Recent Clinical Trials for LITHONATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 1 |
| Paolo Caimi, MD | Phase 1 |
| Fred Hutchinson Cancer Research Center | N/A |
US Patents and Regulatory Information for LITHONATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solvay | LITHONATE | lithium carbonate | CAPSULE;ORAL | 016782-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Solvay | LITHONATE | lithium citrate | SYRUP;ORAL | 017672-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
